Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nexatoclax · LP-118

Small molecule · Inhibitor of B-cell lymphoma-2 (BCL2) and Bcl-extra large (BCL2L1)

Phase 1 Most advanced trial
1 Registered trials

What is Nexatoclax?

Nexatoclax is an orally bioavailable inhibitor of the anti-apoptotic proteins Bcl-2 and Bcl-XL. It binds and inhibits these proteins to restore apoptotic processes in tumor cells. It is being studied in Philadelphia positive acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LP-118
Drug type
Small molecule
Targets
B-cell lymphoma-2 (BCL2), Bcl-extra large (BCL2L1)
Mechanism
Inhibitor of B-cell lymphoma-2 (BCL2) and Bcl-extra large (BCL2L1)
Pathways
apoptosis
Therapy area
Oncology
In trials of
RNA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
AN58D9Y7YZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07614022 Phase 1 Philadelphia Positive Acute Lymphoblastic Leukemia Recruiting RNA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Philadelphia Positive Acute Lymphoblastic Leukemia

Other drugs acting on BCL2 / BCL2L1

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.